Mereo BioPharma: Surges on more positive trial data for bone disorder drug

Mereo BioPharma

14/01/2020 13:03

** U.S.-listed shares of biopharmaceutical co  MREO.O  surge
~31% to $2.96 premarket; stock trading among top pct gainers
across U.S. indexes
    ** Says additional data from its ongoing mid-stage trial of
its treatment for adults with osteogenesis imperfecta (OI), also
known as brittle bone disease, showed positive findings 
    ** Says the treatment, setrusumab, helped in building bone
at the lumbar spine and strengthened bone strength  urn:newsml:reuters.com:*:nGNX2zCfH
    ** Osteogenesis imperfecta is a group of genetic disorders
characterized by fragile bones and reduced bone mass 
    ** The additional data, coupled with the 12-month topline
data MREO had released in November 2019, is supportive of moving
forward with MREO's planned trial in children with OI- MREO
    ** Adds it had a positive meeting with the European
Medicines Agency recently and is preparing for a meeting with
the FDA scheduled for Q1 2020
    ** The mid-stage trial assessed the treatment for 12 months
in 112 patients diagnosed with OI 
    ** Stock fell 80% in 2019

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 7786;))